Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.


Date Title Topic
20 Nov 2017 FDA Approves Sunitinib Malate for Adjuvant Treatment of RCC Genitourinary cancers - Anticancer agents & Biologic therapy
16 Nov 2017 EMA Recommends Extension of Indications for Brentuximab Vedotin Haematologic malignancies - Anticancer agents & Biologic therapy
15 Nov 2017 FDA Grants Approval to Vemurafenib for Erdheim-Chester Disease Anticancer agents & Biologic therapy
14 Nov 2017 Generic Fulvestrant Receives a Positive Opinion from the EMA CHMP Breast cancer - Anticancer agents & Biologic therapy
13 Nov 2017 EMA Recommends Approval of Biosimilar Bevacizumab Anticancer agents & Biologic therapy
10 Nov 2017 FDA Approves Brentuximab Vedotin for the Treatment of Adult Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides Haematologic malignancies - Anticancer agents & Biologic therapy
09 Nov 2017 Assessment, Grading and Management of Acute Toxicities From CAR-T-Cell Therapy Palliative and supportive care - Cancer Immunology and Immunotherapy
08 Nov 2017 FDA Approves Alectinib for ALK Positive Metastatic NSCLC Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
03 Nov 2017 ESMO Members: Survey on Incidence of Organ Rejection in Cancer Patients
06 Nov 2017 Distinct Cancer Profiles Described Among Young Adults Aged 20 to 39 Years Epidemiology/Etiology/Cancer Prevention
03 Nov 2017 FDA Grants Accelerated Approval to Acalabrutinib for Mantle Cell Lymphoma Haematologic malignancies - Anticancer agents & Biologic therapy
02 Nov 2017 Predictive Model May Determine Risk of Subsequent CNS Tumour in Survivors of Childhood Cancer Central nervous system malignancies - Translational research - Cancer in Special Situations
01 Nov 2017 ESMO Media Alert: It is Time for a Concerted European Approach to Defeat Cancer
30 Oct 2017 Rolapitant i.v. Approved by FDA for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy Palliative and supportive care
27 Oct 2017 NICE Announce Nivolumab To Be Available for Some Patients with Head and Neck Cancer Head and neck cancers - Cancer Immunology and Immunotherapy